FT-538
- Generic Name
- FT-538
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 1
Terminated
- Conditions
- Peritoneal CancerSolid TumorOvarian CancerFallopian Tube CancerCancer
- Interventions
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT05708924
- Locations
- 🇺🇸
Masonic Cancer Center - University of Minnesota, Minneapolis, Minnesota, United States
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Solid Tumor, Adult
- Interventions
- Combination Product: Monoclonal antibody - Dose EscalationCombination Product: Monoclonal antibody - Dose Expansion
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT05069935
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Acute Myeloid LeukemiaMyeloid LeukemiaMonocytic Leukemia
- Interventions
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 9
- Registration Number
- NCT04714372
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
FT538 in Subjects With Advanced Hematologic Malignancies
Phase 1
Terminated
- Conditions
- AML, AdultAcute Myeloid LeukemiaMultiple MyelomaMyeloma
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT04614636
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath